O’Brien, John T;
Chouliaras, Leonidas;
Sultana, Janet;
Taylor, John-Paul;
Ballard, Clive;
Aarsland, Dag;
Blanc, Frederic;
... Yarnall, Alison; + view all
(2022)
RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus.
Alzheimer's Research and Therapy
, 14
, Article 169. 10.1186/s13195-022-01103-7.
Preview |
Text
Weil_s13195-022-01103-7.pdf Download (1MB) | Preview |
Abstract
Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacological treatments for Lewy body dementia (which includes both dementia with Lewy bodies and Parkinson’s disease dementia) apart from cholinesterase inhibitors. We reviewed several promising compounds that might potentially be disease-modifying agents for Lewy body dementia and then undertook an International Delphi consensus study to prioritise compounds. We identified ambroxol as the top ranked agent for repurposing and identified a further six agents from the classes of tyrosine kinase inhibitors, GLP-1 receptor agonists, and angiotensin receptor blockers that were rated by the majority of our expert panel as justifying a clinical trial. It would now be timely to take forward all these compounds to Phase II or III clinical trials in Lewy body dementia.
| Type: | Article |
|---|---|
| Title: | RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1186/s13195-022-01103-7 |
| Publisher version: | tps://doi.org/10.1186/s13195-022-01103-7 |
| Language: | English |
| Additional information: | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10160203 |
Archive Staff Only
 |
View Item |
